🔎 Trials Near Me

Home › Type 1 Diabetes › NCT06699810

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

RecruitingPhase 4

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Provide informed consent
* Have a BMI ≥ 28 kg/m2
* Be of African American ancestry
* Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L.

Exclusion Criteria:

* Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
* Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
* Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
* Pregnant
* Diagnosis of diabetes \> 90 days before the presentation of DKA
* Unable to give consent

About the study

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

What is being tested

Sponsor: Emory University · Participants: 12 · Started: Jan 23, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06699810

Locations in the U.S.

GeorgiaEmory University Hospital Midtown, Atlanta
Grady Health System, Atlanta

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.